Published in Blood on June 24, 2008
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood (2010) 5.95
B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. Blood (2008) 2.18
Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood (2014) 1.91
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood (2013) 1.87
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood (2011) 1.75
How I treat CLL up front. Blood (2009) 1.71
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood (2009) 1.70
Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia. Blood (2012) 1.64
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol (2012) 1.56
A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. Clin Cancer Res (2011) 1.54
Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol (2009) 1.48
Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. Haematologica (2010) 1.47
Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. Blood (2011) 1.44
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med (2012) 1.40
Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol (2009) 1.33
Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia (2009) 1.30
Prognostic factors in chronic lymphocytic leukemia-what do we need to know? Nat Rev Clin Oncol (2010) 1.30
Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. Cancer (2010) 1.28
Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am (2013) 1.22
High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood (2009) 1.20
Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells. Haematologica (2010) 1.17
Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. Clin Cancer Res (2013) 1.15
Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia. BMC Bioinformatics (2010) 1.12
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. J Clin Oncol (2011) 1.12
Nrf2 responses and the therapeutic selectivity of electrophilic compounds in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2010) 1.11
ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res (2012) 1.08
Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia (2011) 1.07
Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol (2010) 1.07
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood (2011) 1.07
Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. Epigenomics (2009) 1.02
Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. Proc Natl Acad Sci U S A (2013) 1.00
White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia. Haematologica (2010) 0.98
Genetic abnormalities in chronic lymphocytic leukemia: where we are and where we go. Biomed Res Int (2014) 0.98
Stem cell transplantation in chronic lymphocytic leukemia. Biol Blood Marrow Transplant (2009) 0.96
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. Blood (2014) 0.95
Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. PLoS One (2011) 0.94
Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol (2014) 0.93
LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. Haematologica (2011) 0.93
Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. Haematologica (2009) 0.91
The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience. Br J Haematol (2016) 0.88
Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera. Mol Med (2011) 0.88
Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. Blood Rev (2010) 0.87
Inhibitors of B-cell receptor signaling for patients with B-cell malignancies. Cancer J (2012) 0.87
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood (2016) 0.86
ENCODE tiling array analysis identifies differentially expressed annotated and novel 5' capped RNAs in hepatitis C infected liver. PLoS One (2011) 0.86
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. J Transl Med (2010) 0.86
Relative seroprevalence of human herpes viruses in patients with chronic lymphocytic leukaemia. Eur J Clin Invest (2009) 0.85
The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. Leukemia (2015) 0.84
CD14(+)HLA-DR(low/-) expression: A novel prognostic factor in chronic lymphocytic leukemia. Oncol Lett (2014) 0.84
Opposite Prognostic Significance of Cellular and Serum Circulating MicroRNA-150 in Patients with Chronic Lymphocytic Leukemia. Mol Med (2015) 0.83
Younger patients with chronic lymphocytic leukemia benefit from rituximab treatment: A single center study in China. Oncol Lett (2013) 0.83
Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation. Cytometry B Clin Cytom (2011) 0.82
Cross-talk between DNA methylation and active histone modifications regulates aberrant expression of ZAP70 in CLL. J Cell Mol Med (2012) 0.82
Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. Leukemia (2014) 0.82
Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans. Blood (2012) 0.81
High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients. Med Oncol (2013) 0.81
Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res (2010) 0.81
Identification of therapeutic candidates for chronic lymphocytic leukemia from a library of approved drugs. PLoS One (2013) 0.81
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. J Transl Med (2012) 0.81
Emerging roles for the FCRL family members in lymphocyte biology and disease. Curr Top Microbiol Immunol (2014) 0.81
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw (2015) 0.81
Detection methods of ZAP-70 in chronic lymphocytic leukemia. Clin Exp Med (2011) 0.80
Developing Molecular Signatures for Chronic Lymphocytic Leukemia. PLoS One (2015) 0.80
Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients. Biomed Res Int (2014) 0.80
Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. Exp Hematol (2010) 0.79
Cyclic nucleotide phosphodiesterase 7B mRNA: an unfavorable characteristic in chronic lymphocytic leukemia. Int J Cancer (2011) 0.78
Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. Clin Cancer Res (2015) 0.78
Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. Eur J Haematol (2011) 0.78
High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. J Mol Diagn (2010) 0.77
Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling. Cell Death Dis (2014) 0.77
Chronic lymphocytic leukemia: a clinical review including Korean cohorts. Korean J Intern Med (2016) 0.77
Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis. J Mol Diagn (2010) 0.77
Allogeneic transplantation for chronic lymphocytic leukemia. Mediterr J Hematol Infect Dis (2010) 0.76
Selective immunophenotyping for diagnosis of B-cell neoplasms: immunohistochemistry and flow cytometry strategies and results. Appl Immunohistochem Mol Morphol (2013) 0.75
Modulation of B-cell receptor and microenvironment signaling by a guanine exchange factor in B-cell malignancies. Cancer Biol Med (2016) 0.75
Fc Receptor-Like Proteins in Pathophysiology of B-cell Disorder. J Clin Cell Immunol (2016) 0.75
Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. Oncotarget (2016) 0.75
Chronic Lymphocytic Leukemia Prognostic Index: A New Integrated Scoring System to Predict the Time to First Treatment in Chinese Patients with Chronic Lymphocytic Leukemia. Chin Med J (Engl) (2017) 0.75
Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia. Onco Targets Ther (2016) 0.75
Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia. Contemp Oncol (Pozn) (2013) 0.75
Role of allogeneic transplantation in patients with chronic lymphocytic leukemia in the era of novel therapies: a review. Ther Adv Hematol (2014) 0.75
Cytogenetic Abnormalities with Interphase FISH Method and Clinical Manifestation in Chronic Lymphocytic Leukemia Patients in North-East of Iran. Int J Hematol Oncol Stem Cell Res (2017) 0.75
Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia (2017) 0.75
National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood (1996) 13.35
Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood (1999) 11.57
Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood (1999) 11.50
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med (2003) 6.82
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2002) 3.38
V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood (2002) 3.17
ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet (2004) 2.79
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood (2004) 2.30
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol (2006) 2.15
CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood (2001) 2.14
Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol (2001) 2.10
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia. Blood (2007) 2.00
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. Blood (2006) 1.95
Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood (2008) 1.65
Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood (2001) 1.55
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia (2005) 1.47
CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential. Blood (2007) 1.35
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood (2006) 1.26
Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood (2005) 1.24
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia (2002) 1.21
When and how to treat chronic lymphocytic leukemia. N Engl J Med (2000) 1.12
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol (2005) 1.07
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia (2003) 1.06
Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Blood (2000) 1.02
CLL biology and prognosis. Hematology Am Soc Hematol Educ Program (2005) 1.02
CD38 as a prognostic marker in CLL. Hematology (2005) 0.99
Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer (2005) 0.99
The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol (2006) 0.99
The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. Best Pract Res Clin Haematol (2007) 0.97
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Haematologica (2008) 0.95
Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol (2003) 0.94
The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol (2005) 0.94
CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood (2001) 0.90
ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. Leukemia (2006) 0.88
Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis. Arch Pathol Lab Med (2007) 0.86
CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J (2004) 0.85
CD38 expression in B-chronic lymphocytic leukemia: association with clinical presentation and outcome in 155 patients. Haematologica (2002) 0.85
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. Am J Hematol (2007) 0.84
Regulation of protein tyrosine kinase activation by the T-cell antigen receptor zeta chain. Cold Spring Harb Symp Quant Biol (1992) 0.83
Molecular and genetic insights into T cell antigen receptor signal transduction. Adv Exp Med Biol (1994) 0.81
B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. J Clin Pathol (2006) 0.80
Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia. Folia Histochem Cytobiol (2005) 0.80
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics (2004) 19.05
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med (2013) 16.33
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med (2002) 14.01
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Chronic lymphocytic leukemia. N Engl J Med (2005) 9.99
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med (2004) 7.04
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med (2014) 6.73
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell (2002) 6.64
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood (2011) 5.98
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.69
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood (2005) 5.21
Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol (2011) 5.14
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med (2015) 5.08
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood (2011) 5.06
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med (2014) 4.98
Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol (2010) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 4.65
Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy. J Infect Dis (2008) 4.61
Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood (2008) 4.61
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood (2013) 4.17
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest (2005) 3.99
Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Invest (2008) 3.89
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci U S A (2010) 3.86
Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res (2005) 3.79
Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell (2007) 3.58
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. Blood (2006) 3.48
Adult Burkitt leukemia and lymphoma. Blood (2004) 3.46
Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev (2007) 3.45
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood (2002) 3.38
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors. Blood (2007) 3.29
Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A (2013) 3.25
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol (2007) 3.23
High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood (2008) 3.19
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood (2008) 3.19
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2003) 3.18
Global warming preceded by increasing carbon dioxide concentrations during the last deglaciation. Nature (2012) 3.17
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol (2007) 3.09
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol (2006) 3.06
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol (2005) 3.05
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood (2002) 3.03
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood (2014) 2.94
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Ice-shelf collapse from subsurface warming as a trigger for Heinrich events. Proc Natl Acad Sci U S A (2011) 2.83